Home » Newsletters » BioWorld Science

BioWorld Science

March 24, 2017

View Archived Issues

Identification of AAT-008, a potent and selective prostaglandin EP4 receptor antagonist

FDA awards orphan drug designation to Moleculin's liposomal annamycin for AML

RL-71 shows promise in suppressing tumor growth in triple-negative breast cancer mouse model

Pfizer initiates phase II study of PF-06741086 in severe hemophilia

EMA accepts for review brexpiprazole MAA for schizophrenia in adults

EMA grants orphan drug designation to NiCord in HSCT

BioLineRx acquires Agalimmune

Herantis gets Swedish clearance to begin phase I/II trial of CDNF in Parkinson's disease

Toxicity and pharmacokinetics of myocardial infarction candidate RUC-4 studied in vivo

Merck & Co. initiates phase IIa study of MK-8189 in schizophrenia

Janssen identifies novel cannabinoid receptor 1 inverse agonists

Pharmacokinetic and pharmacodynamic data presented from first clinical trial of BMS-962212

Santen Pharmaceutical patents glucocorticoid receptor agonists

Janssen Pharmaceutica synthesizes novel analgesic compounds

Bristol-Myers Squibb synthesizes novel myeloperoxidase and/or eosinophil peroxidase inhibitors

Ocean University of China describes new anti-HSV-1 compounds

ImmunoCellular Therapeutics and Memgen sign immuno-oncology collaboration letter of intent

NR4A1, a novel target for the treatment of alveolar rhabdomyosarcoma

FDA approves Bavencio for metastatic Merkel cell carcinoma

European Commission approves Amgen's adalimumab biosimilar Amgevita

Torii seeks to expand Japanese label for Miticure to include pediatric patients

FDA grants breakthrough therapy designation to Rituxan for pemphigus vulgaris

Merrimack initiates phase I study of MM-310 in solid tumors

FDA accepts for filing Solosec NDA for bacterial vaginosis

FDA approves Symproic for opioid-induced constipation in adults with chronic non-cancer pain

IDMC recommends continuation of phase II/III trial of NBTXR-3 in soft tissue sarcoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...